ArticleHealth science reports2026
Soft Tissue Sarcoma Burden and Research Productivity: Global Patterns and Disparities, 1990-2021.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Soft Tissue Sarcoma Burden and Research Productivity: Global Patterns and Disparities, 1990-2021.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Soft tissue sarcoma (STS) is a rare and diverse type of cancer, with a disproportionate incidence and limited global epidemiological studies. This study aims to analyze the long-term trends and epidemiological features of the global burden of STS from 1990 to 2021 and to reveal the global research productivity on STS. Methods: The global burden of STS was analyzed using the methods and results of the 2021 Global Burden of Disease (GBD) Study, focusing on incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and corresponding age-standardized rates. We also analyzed STS epidemiological trends using joinpoint and age-period-cohort (APC) methods, and assessed research productivity through a composite metric incorporating funding inputs, scientific outputs, drug development pipelines, and clinical trial activity. Results: In 2021, it was estimated that there were approximately 96,201 cases of sarcoma worldwide, resulting in 50,203 deaths. The age-standardized incidence rate was 1.16 cases per 100,000 population-years (95% uncertainty interval [UI] 1.0-1.41), while the mortality rate stood at 20.54 deaths per 100,000 population-years (95% UI: 17.46-26.09). Socioeconomic gradients were evident, with a higher incidence in high-HDI countries and mortality rates that were twice as high in low-HDI countries than in middle-HDI countries. The impacts of age, period, and cohort on mortality rates varied. The research productivity of STS have generally increased across the Socio-Demographic Index (SDI), but effective treatments remain lacking. Conclusion: The global burden of STS relatively stable from 1990 to 2021, with notable geographic disparities. Global investment in basic research related to sarcomas has increased, but treatment options remain limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.